Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAP | Q12884 | 2/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 15/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 14/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL2670558 | 0.95 | FAP (0.71) | FAPCYP3A4CYP2D6 | |
| SCHEMBL3672191 | 0.89 | FAP (0.70) | FAPCYP3A4CYP2D6 | |
| SCHEMBL28395512 | 0.86 | FAP (0.85) | FAPCYP3A4CYP2D6 | |
| SCHEMBL29402746 | 0.86 | FAP (0.85) | FAPCYP3A4CYP2D6 | |
| SCHEMBL14507066 | 0.86 | FAP (0.85) | FAPCYP3A4CYP2D6 | |
| Fumaric Acid SCHEMBL4212549 | 0.85 | FAP (0.72) | FAPCYP3A4CYP2D6 | |
| Tenofovir Disoproxil SCHEMBL15241296 | 0.82 | FAP (0.96) | FAPCYP3A4CYP2D6 | |
| Tenofovir Disoproxil SCHEMBL29376425 | 0.81 | FAP (1.00) | FAPCYP3A4CYP2D6 | |
| Tenofovir Disoproxil SCHEMBL18907027 | 0.81 | FAP (1.00) | FAPCYP3A4CYP2D6 | |
| Tenofovir Disoproxil SCHEMBL52793 | 0.81 | FAP (1.00) | FAPCYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2932970-A1 | ANTIVIRAL THERAPY | VIIV Healthcare Company (US) | 2015-10-21 | — | — | EP | claimed |
| EP-1720856-B1 | HIV INTEGRASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2013-08-14 | — | — | EP | claimed |
| WO-2009075960-A1 | CCR5 ANTAGONISTS AS THERAPEUTIC AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-06-18 | — | — | WO | claimed |
| WO-2009058923-A1 | CCR5 ANTAGONISTS AS THERAPEUTIC AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-05-07 | — | — | WO | claimed |
| US-20090053172-A1 | HETEROCYCLIC COMPOUNDS AS CCR5 ANTAGONISTS | AQUINO CHRISTOPHER JOSEPH | 2009-02-26 | — | — | US | claimed |
| EP-1622615-A4 | NAPHTHYRIDINE INTEGRASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2009-02-18 | — | — | EP | claimed |
| EP-1569931-B1 | HETEROCYCLIC COMPOUNDS AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2008-10-08 | — | — | EP | claimed |
| US-20080234231-A1 | Hiv Integrase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2008-09-25 | — | — | US | claimed |
| US-20080214527-A1 | Hiv Integrase Inhibitors | SHIONOGI & CO. LTD (JP) | 2008-09-04 | — | — | US | claimed |
| US-20080214503-A1 | Hiv Integrase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2008-09-04 | — | — | US | claimed |
| EP-1569646-A2 | PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-09-07 | — | — | EP | claimed |
| EP-1569933-A1 | PYRROLIDINE AND AZETIDINE COMPOUNDS AS CCR5 ANTAGONISTS | SmithKline Beecham Corporation (US) | 2005-09-07 | — | — | EP | claimed |
| EP-1569931-A1 | HETEROCYCLIC COMPOUNDS AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-09-07 | — | — | EP | claimed |
| WO-2005077050-A2 | HIV INTEGRASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-08-25 | — | — | WO | claimed |
| WO-2004101512-A2 | NAPHTHYRIDINE INTEGRASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-11-25 | — | — | WO | claimed |
| WO-2004055016-A1 | PYRROLIDINE AND AZETIDINE COMPOUNDS AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-07-01 | — | — | WO | claimed |
| WO-2004055011-A1 | HETEROCYCLIC COMPOUNDS AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-07-01 | — | — | WO | claimed |
| WO-2004055012-A1 | INDANE COMPOUNDS AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-07-01 | — | — | WO | claimed |
| WO-2004054974-A2 | PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-07-01 | — | — | WO | claimed |
| US-20040122064-A1 | Benzophenones as inhibitors of reverse transcriptase | SMITHKLINE BEECHAM CORPORATION | 2004-06-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090053172-A1 | HETEROCYCLIC COMPOUNDS AS CCR5 ANTAGONISTS | CCR5, CXCR3, CCR1 | FAP 4290/4885CYP3A4 576/4885CYP2D6 1070/4885 |
| US-20040122064-A1 | Benzophenones as inhibitors of reverse transcriptase | POLRMT, ELL, POLR2A | FAP 2835/4885CYP3A4 78/4885CYP2D6 131/4885 |
| US-20080214527-A1 | Hiv Integrase Inhibitors | API5, ING2, SAMHD1 | FAP 3526/4885CYP3A4 1166/4885CYP2D6 3048/4885 |
| US-20080214503-A1 | Hiv Integrase Inhibitors | SAMHD1, ACIN1, API5 | FAP 3228/4885CYP3A4 1163/4885CYP2D6 3174/4885 |
| US-20080234231-A1 | Hiv Integrase Inhibitors | ING2, API5, SAMHD1 | FAP 3304/4885CYP3A4 1298/4885CYP2D6 3175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.